All Stories

  1. Paradoxical effect of anticancer treatment with auranofin

    Article • Antioxidants, November 2025, MDPI AG

    Elias Arner, Michael Y. Bonner

  2. Glycan Activation of Clec4b Induces Reactive Oxygen Species Protecting against Neutrophilia and Arthritis

    Article • Antioxidants, December 2021, MDPI AG

    Michael Y. Bonner

  3. An Optimized Model of Hypertrophic Preconditioning Confers Cardioprotection in the Mouse

    Article • Journal of Surgical Research, August 2021, Elsevier

    Michael Y. Bonner

  4. Correction: da Costa et al. Establishment of a Temperature-Sensitive Model of Oncogene-Induced Senescence in Angiosarcoma Cells. Cancers 2020, 12, 395

    Article • Cancers, April 2021, MDPI AG

    Michael Y. Bonner

  5. Endophilin A2 deficiency protects rodents from autoimmune arthritis by modulating T cell activation

    Article • Nature Communications, January 2021, Springer Science + Business Media

    Michael Y. Bonner

  6. Establishment of a Temperature-Sensitive Model of Oncogene-Induced Senescence in Angiosarcoma Cells

    Article • Cancers, February 2020, MDPI AG

    Michael Y. Bonner

  7. Selenium unmasks protective iron armor: A possible defense against cutaneous inflammation and cancer

    Article • Biochimica et Biophysica Acta (BBA) - General Subjects, November 2018, Elsevier

    Michael Y. Bonner

  8. Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis

    Article • Scientific Reports, September 2017, Springer Science + Business Media

    Michael Y. Bonner

  9. Activation of Protein Kinase C ε in Merkel Cell Polyomavirus–Induced Merkel Cell Carcinoma

    Article • JAMA Dermatology, September 2017, American Medical Association (AMA)

    Michael Y. Bonner

  10. Comprehensive profiling of H-Ras signalling in angiosarcoma endothelium

    Article • Clinical and Experimental Dermatology, July 2017, Oxford University Press (OUP)

    Michael Y. Bonner

  11. Targeting the duality of cancer

    Article • npj Precision Oncology, June 2017, Springer Science + Business Media

    Michael Y. Bonner

  12. Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3

    Article • Oncogene, June 2017, Springer Science + Business Media

    Michael Y. Bonner

  13. 103 Blockade of hippo pathway effector YAP1 with shRNA attenuates vascular development in Hemangioma Bend3 cells in vivo

    Article • Journal of Investigative Dermatology, May 2017, Elsevier

    Michael Y. Bonner

  14. Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis

    Article • Breast Cancer Research, March 2017, Springer Science + Business Media

    Michael Y. Bonner

  15. Honokiol protects skin cells against inflammation, collagenolysis, apoptosis, and senescence caused by cigarette smoke damage

    Article • International Journal of Dermatology, February 2017, Wiley

    Michael Y. Bonner

  16. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis

    Article • Oncotarget, October 2016, Impact Journals, LLC

    Michael Y. Bonner

  17. Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies

    Article • Molecules, July 2016, MDPI AG

    Michael Y. Bonner

  18. Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia

    Article • Oncotarget, July 2016, Impact Journals, LLC

    Michael Y. Bonner

  19. Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model

    Article • Oncotarget, July 2016, Impact Journals, LLC

    Michael Y. Bonner

  20. Tuberculosis verrucosa cutis lesions exhibit a greater microvessel count than lupus vulgaris lesions

    Article • Experimental Dermatology, May 2016, Wiley

    Michael Y. Bonner

  21. Use of Polyphenolic Compounds in Dermatologic Oncology

    Article • American Journal of Clinical Dermatology, May 2016, Springer Science + Business Media

    Michael Y. Bonner

  22. 106 A novel system to study the signaling of oncogene-induced senescence

    Article • Journal of Investigative Dermatology, May 2016, Elsevier

    Michael Y. Bonner

  23. Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect

    Article • Journal of Investigative Dermatology, March 2016, Elsevier

    Michael Y. Bonner

  24. Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanomain vivo

    Article • Oncotarget, February 2016, Impact Journals, LLC

    Michael Y. Bonner

  25. Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer

    Article • Oncotarget, August 2015, Impact Journals, LLC

    Michael Y. Bonner

  26. Solenopsin A and analogs exhibit ceramide-like biological activity

    Article • Vascular Cell, May 2015, Publiverse Online S.R.L

    Michael Y. Bonner

  27. Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner

    Article • Oncotarget, April 2015, Impact Journals, LLC

    Michael Y. Bonner

  28. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3

    Article • Nature Communications, April 2015, Springer Science + Business Media

    Michael Y. Bonner

  29. Inactivation of NADPH Oxidases NOX4 and NOX5 Protects Human Primary Fibroblasts from Ionizing Radiation-Induced DNA Damage

    Article • Radiation Research, February 2015, Radiation Research Society

    Michael Y. Bonner

  30. NADPH oxidase 4 is a critical mediator in Ataxia telangiectasia disease

    Article • Proceedings of the National Academy of Sciences, February 2015, Proceedings of the National Academy of Sciences

    Michael Y. Bonner

  31. Abstract LB-61: Inhibiting “Dedifferentiation” in breast cancer cells using Honokiol - a plant derived polyphenol

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Michael Y. Bonner

  32. Abstract LB-187: Novel mechanistic insights into the bioactive compound honokiol-mediated inhibition of epithelial to mesenchymal transition in breast cancer: Therapeutic modulation of miR-34a via tumor suppressor LKB1

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Michael Y. Bonner

  33. The Antioxidant Paradox: What are Antioxidants and How Should They Be Used in a Therapeutic Context for Cancer

    Article • Future Medicinal Chemistry, August 2014, Taylor & Francis

    Michael Y. Bonner

  34. Honokiol Enhances Paclitaxel Efficacy in Multi-Drug Resistant Human Cancer Model through the Induction of Apoptosis

    Article • PLOS One, February 2014, PLOS

    Michael Y. Bonner

  35. Honokiol inhibits epithelial—mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E‐cadherin axis

    Article • Molecular Oncology, January 2014, Wiley

    Michael Y. Bonner

  36. Honokiol inhibits androgen receptor activity in prostate cancer cells

    Article • The Prostate, December 2013, Wiley

    Michael Y. Bonner

  37. In Vivo Gram Staining of Tinea Versicolor

    Article • JAMA Dermatology, August 2013, American Medical Association (AMA)

    Michael Y. Bonner

  38. Identifying new small molecule anti-invasive compounds for glioma treatment

    Article • Cell Cycle, July 2013, Taylor & Francis

    Michael Y. Bonner

  39. Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78

    Article • British Journal of Cancer, June 2013, Springer Science + Business Media

    Michael Y. Bonner

  40. Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases

    Article • Journal of the American Academy of Dermatology, August 2012, Elsevier

    Michael Y. Bonner

  41. Targeting NADPH oxidases for the treatment of cancer and inflammation

    Article • Cellular and Molecular Life Sciences, May 2012, Springer Science + Business Media

    Michael Y. Bonner

  42. Abstract 153: Honokiol, a promising small molecular weight natural agent, activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Michael Y. Bonner

  43. Anti-Invasive Adjuvant Therapy with Imipramine Blue Enhances Chemotherapeutic Efficacy Against Glioma

    Article • Science Translational Medicine, March 2012, American Association for the Advancement of Science

    Michael Y. Bonner

  44. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis

    Article • Breast Cancer Research, February 2012, Springer Science + Business Media

    Michael Y. Bonner

  45. Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia

    Article • Vascular Cell, January 2012, Publiverse Online S.R.L

    Michael Y. Bonner

  46. Posterior Lumbar Vein Off the Retrohepatic Inferior Vena Cava: A Novel Anatomical Variant With Surgical Implications

    Article • The Journal of Urology, January 2012, Wolters Kluwer Health

    Michael Y. Bonner

  47. 1766 POSTERIOR LUMBAR VEIN OFF THE RETROHEPATIC INFERIOR VENA CAVA: A NOVEL ANATOMICAL VARIANT WITH SURGICAL IMPLICATIONS

    Article • The Journal of Urology, April 2011, Wolters Kluwer Health

    Michael Y. Bonner

  48. High level expression of angiopoietin-2 in human abscesses

    Article • Journal of the American Academy of Dermatology, January 2011, Elsevier

    Michael Y. Bonner

  49. Abstract 3702: Novel nanoparticle-delivered compound, Imipramine Blue, halts glioma invasion by affecting actin dynamics

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Michael Y. Bonner

  50. Hemangiomas, Angiosarcomas, and Vascular Malformations Represent the Signaling Abnormalities of Pathogenic Angiogenesis

    Article • Current Molecular Medicine, November 2009, Bentham Science Publishers

    Michael Y. Bonner

  51. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice

    Article • Journal of Clinical Investigation, July 2009, American Society for Clinical Investigation

    Michael Y. Bonner